Advances in Gastroretentive Floating Drug Delivery Systems: A Comprehensive Review

The oral route remains the gold standard for pharmaceutical administration, representing over 60% of all commercialized dosage forms due to its unmatched patient compliance, ease of ingestion, and formulation flexibility [1]. However, the development of effective oral controlled-release matrices is frequently throttled by a matrix of physiological hurdles within the human gastrointestinal (GI) tract [2]. Prominent among these constraints are the highly variable gastric emptying rates, transient transit times across the small intestine, and the highly localized regional absorption windows exhibited by numerous critical therapeutic molecules [3]. When an conventional sustained-release dosage form transits past its primary absorption window in the upper small intestine, it enters regions with suboptimal permeability or unfavorable pH environments, resulting in incomplete drug extraction and drastically compromised systemic bioavailability [4]. To circumvent these biological limitations, the pharmaceutical scientific community has heavily invested in the engineering of Gastroretentive Drug Delivery Systems (GRDDS) [5]. These specialized platforms are designed to remain localized within the gastric cavity for extended durations, systematically resisting the physiological emptying mechanisms of the stomach [6]. By acting as a stationary reservoir in the gastric lumen, GRDDS continuously release the active pharmaceutical ingredient (API) in a controlled manner, guaranteeing a steady and prolonged influx of the drug directly into the proximal segments of the small intestine, which typically serves as the primary absorption window [7]. This site-specific release pattern minimizes systemic side effects, prevents toxic plasma fluctuations, and reduces the required dosing frequency, thereby directly bolstering patient compliance and overall therapeutic outcomes [8].

2. Need for Gastroretentive Drug Delivery Systems

The fundamental impetus for developing GRDDS arises from the pharmacodynamics and pharmacokinetic mismatches inherent to conventional dosage forms when delivering specific drug candidates [9]. Conventional extended-release systems lack site-retention capabilities; thus, their transit through the stomach and intestine is strictly governed by systemic peristalsis, irrespective of whether the drug has been completely discharged [10]. This creates an urgent clinical need for gastroretention in several scenarios: first, for drugs that act locally within the stomach, such as antacids, mucosal protectants, and antimicrobial agents utilized in the eradication of Helicobacter pylori [11]. Maintaining a high local drug concentration directly at the gastric mucosal surface significantly maximizes the bactericidal efficacy while minimizing systemic toxicity [12].

Second, gastroretention is essential for drugs that exhibit narrow absorption windows, meaning they are exclusively absorbed from the stomach or the proximal segments of the duodenum and jejunum [13]. Examples include levodopa, riboflavin, and metformin. When these drugs are incorporated into conventional matrices, any acceleration in gastric emptying pushes the dosage form into the colon, where absorption is negligible, causing therapeutic failure [14]. Third, molecules that are unstable or poorly soluble in the alkaline environment of the lower intestine benefit significantly from a prolonged gastric residence [15]. By keeping the drug dissolved within the highly acidic gastric juice (pH 1.2–2.5), the system ensures optimal solubility conditions before the drug moves down the intestinal tract [16].

3. Anatomy and Physiology of the Stomach Related to Gastroretention

Designing effective gastroretentive systems requires a deep understanding of the unique anatomical structure and complex motor patterns of the human stomach [17]. Anatomically, the stomach is divided into three major functional zones: the fundus, the body (corpus), and the antrum (pylorus) [18]. The fundus and proximal body act as a reservoir for ingested material, exerting a constant, gentle basal pressure to guide contents toward the distal region [19]. The distal body and antrum function as the primary mixing and grinding organ, generating forceful peristaltic contractions that break down large food particles and push them through the narrow pyloric sphincter into the duodenum [20]. The pyloric sphincter acts as a strict physiological sieve, preventing the passage of solid particles larger than approximately 1.5 to 2.0 mm during the digestive phase [21]. The primary physiological challenge to gastroretention is the Interdigestive Myoelectric Complex, commonly referred to as the Migrating Motor Complex (MMC) [22]. The MMC is a highly organized cyclic pattern of electromechanical activity observed in the empty stomach during the fasting state, repeating every 90 to 120 minutes [23]. It consists of four distinct consecutive phases: Phase I (Basal phase), lasting 40–60 minutes, characterized by absolute quiescence and rare contractions; Phase II (Pre-burst phase), lasting 20–40 minutes, marked by irregular, intermittent contractions that gradually increase in intensity; Phase III (Burst phase), lasting 5–15 minutes, characterized by intense, regular, and regular house-keeper contractions that sweep all residual contents, including large undigested material, through the wide-open pylorus; and Phase IV, a short transitional period of 0–5 minutes leading back to Phase I [24]. For non-floating systems, survival past Phase III is exceptionally difficult unless the device is significantly large or highly bioadhesive [25].

4. Principles of Floating Drug Delivery Systems

Among the various technological subcategories of gastroretention—which include high-density sinking matrices, bioadhesive networks, swelling or expandable systems, and magnetic platforms—Floating Drug Delivery Systems (FDDS) have achieved the highest degree of commercial success and experimental reproducibility [26]. The core operating principle of FDDS relies on the physical properties of buoyancy [27]. To achieve reliable buoyancy, the bulk density of the formulation must remain consistently lower than the density of the native gastric fluid, which is approximately 1.004 g/cm³ [28]. When the device is ingested, it quickly hydrates upon contact with the gastric juice, maintaining an effective density below 1.004 g/cm³ while remaining afloat on the surface of the gastric contents within the fundus or body of the stomach [29]. By remaining floating at the topmost layer of the gastric contents, the dosage form is safely insulated from the aggressive propulsive waves generated by the antral musculature [30]. Consequently, the system remains positioned inside the stomach for a prolonged period, continuously releasing the dissolved drug into the fluid [31]. As long as the system maintain a density below that of the gastric juice, it will resist emptying during Phases I and II of the MMC [32]. Once the drug payload is completely exhausted, the remaining spent polymeric matrix loses its structural integrity, increases in bulk density, dissolves, or collapses, allowing it to be safely eliminated from the GI tract via normal peristalsis [33].

5. Classification of Gastroretentive Floating Drug Delivery Systems

Floating drug delivery systems can be broadly categorized into two major classes based on their operational mechanism and formulation composition: Effervescent (Gas-generating) Systems and Non-effervescent Systems [34]. Each configuration utilizes unique material architectures to achieve the desired buoyant state, as described below.

5.1 Effervescent (Gas-Generating) Systems

Effervescent systems contain a gas-generating component, typically comprising an organic acid (such as citric acid or tartaric acid) and a carbonate or bicarbonate salt (such as sodium bicarbonate or calcium carbonate) matrixed alongside hydrophilic swelling polymers [35]. When this system comes into contact with the acidic environment of the gastric juice, a chemical reaction is instantly triggered, generating carbon dioxide (CO₂) gas [36]. The liberated CO₂ gas becomes trapped within the rapidly hydrating, highly viscous gel layer formed by the surrounding hydrophilic polymers [37]. This trapped gas causes the device to expand and dramatically lowers its bulk density below 1.004 g/cm³, driving rapid and sustained flotation [38]. Effervescent formulations can be further sub-classified into single-unit floating tablets or multi-unit systems like effervescent floating beads or microballoons [39].

5.2 Non-Effervescent Systems

Non-effervescent systems rely exclusively on the swelling and entrapment characteristics of highly cohesive, gel-forming hydrocolloids or low-density lipid excipients, without any gas-producing chemical reactions [12]. Upon ingestion, the outer layers of the polymer rapidly absorb fluid and swell to create a thick, continuous gel barrier [15]. Air becomes trapped within the dry core of the unhydrated polymer matrix during this swelling process, keeping the overall density below unity [18]. These systems are further divided into Hydrodynamically Balanced Systems (HBS), which incorporate high levels of cellulose derivatives; hollow microspheres (microballoons) prepared by emulsion-solvent evaporation; and multi-layer floating configurations that segregate the buoyant layer from the drug reservoir layer [21].

6. Mechanism of Floating Drug Delivery Systems

The mechanism of buoyancy in FDDS can be mathematically explained by analyzing the balance of hydrodynamic forces acting on a solid body submerged in fluid [24]. The net vertical force ($F$) acting on the system is a function of the gravity force ($F_g$) acting downwards and the buoyancy force ($F_b$) pushing upwards, which can be defined by the following expression:

F = F_b - F_g = ( ho_f - ho_s) \cdot V \cdot g

where ρ_f represents the density of the gastric fluid, ρ_s represents the bulk density of the solid floating dosage form, V is the total hydrodynamic volume of the expanded device, and g is the acceleration due to gravity [27]. For a formulation to exhibit positive upward buoyancy, the net force $F$ must remain positive, which mathematically dictates that ρ_s < ρ_f [29].

Figure 1: Mechanistic Operation of Effervescent vs. Non-Effervescent Floating Systems.

As illustrated in Figure 1, the physical pathway to achieving this low density varies between the two types. In effervescent matrices, fluid penetration triggers a chemical reaction that fills the gel matrix with CO₂ bubbles. In non-effervescent systems, fluid intake triggers rapid polymer swelling, forming a thick gel boundary layer that encapsulates air pockets within the dry inner core. Both pathways achieve the same outcome: reducing the bulk density below that of the gastric fluid to ensure reliable flotation [31].

7. Advantages

Floating drug delivery systems offer substantial clinical and technological benefits over conventional or alternative gastroretentive configurations [33]. A primary advantage is their complete independence from mucocutaneous adhesion mechanics, allowing them to function reliably without causing local irritation or damage to the delicate gastric mucosa—a frequent limitation of bioadhesive systems [35]. Additionally, FDDS are highly effective at maintaining a constant, uniform therapeutic drug level in the plasma, which minimizes toxicological spikes and sub-therapeutic drops [36]. Table 1 summarizes the main therapeutic advantages of FDDS.

Table 1: Strategic Advantages of Floating Drug Delivery Systems.

LIMITATIONS

Despite their numerous benefits, FDDS face several specific physiological and formulation challenges that can limit their real-world clinical efficacy [38]. A key constraint is the strict requirement for a minimum volume of fluid within the gastric cavity to allow the system to float effectively [39]. If the patient is in a fasted or dehydrated state, the lack of sufficient gastric juice prevents the formulation from floating, causing it to settle on the antrum and be rapidly expelled by Phase III MMC waves [2]. Furthermore, FDDS are not suitable for drug candidates that suffer from stability or solubility issues within the highly acidic gastric fluid, or those that undergo significant degradation by pepsin [4]. Another challenge is the high variability in gastric emptying times among patients, which is influenced by factors such as age, gender, disease state, and posture [6]. For instance, a patient in a supine or flat lying position may experience premature emptying of the floating device, as it can drift toward the pyloric sphincter and enter the duodenum [9]. Finally, formulating high-dose drugs into floating systems is difficult; adding large amounts of active ingredients often increases the overall density of the matrix, making it challenging to maintain buoyancy without creating an unmanageably large tablet or capsule [11].

9. Factors Affecting Gastric Retention

The operational performance and in vivo residence time of floating systems are highly dependent on several interconnected physiological, formulation, and patient-specific factors [13]:

• Density and Size: The bulk density of the formulation is the primary factor determining buoyancy. A density less than 1.004 g/cm³ is required for flotation. Additionally, the physical size of the device must be optimized; single-unit formulations generally require a diameter greater than 7–10 mm to resist premature passage through the pylorus during intermediate contractions [16].
• Caloric Content and Food Intake: Gastric retention times change dramatically between the fed and fasted states. Ingesting meals rich in fats or proteins triggers a significant delay in gastric emptying, switching the stomach to a digestive motor pattern that closes the pylorus and allows floating devices to remain buoyant for much longer periods [18].
• Concomitant Medications: Administering floating systems alongside drugs that alter GI motility can significantly impact performance. For example, co-administering prokinetic agents like metoclopramide or erythromycin accelerates gastric emptying, reducing retention time. Conversely, anticholinergic agents like propantheline delay motility, extending gastric residence [22].
• Patient Demographics and Physiology: Elderly patients often exhibit naturally delayed gastric emptying rates, which can prolong retention times. Additionally, pathological states such as diabetic gastroparesis extend gastric residence, whereas conditions like Crohn's disease or hyperthyroidism accelerate intestinal transit [25].

10. Polymers Used in Floating Drug Delivery Systems

Selecting appropriate polymeric carriers is crucial for designing robust, functional floating drug delivery networks [28]. The polymers must exhibit rapid hydration kinetics to form a cohesive gel layer, while maintaining sufficient mechanical strength to withstand gastric shear forces and resist premature erosion [30]. Table 2 compares key natural and synthetic polymers commonly used in FDDS formulations.

Table 2: Comparative Profile of Key Polymers in Floating Drug Delivery Formulations.